Earnings summaries and quarterly performance for Beyond Air.
Executive leadership at Beyond Air.
Board of directors at Beyond Air.
Research analysts who have asked questions during Beyond Air earnings calls.
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
5 questions for XAIR
Also covers: AFMD, ALDX, ARCT +14 more
Marie Thibault
BTIG
4 questions for XAIR
Also covers: ABT, ARAY, ATRC +15 more
Jason Bednar
Piper Sandler Companies
3 questions for XAIR
Also covers: ALGN, COO, EDAP +17 more
JW
Justin Walsh
Jones Trading
3 questions for XAIR
Also covers: ACHV, BLRX, GTBP +7 more
MK
Matthew Kaplan
Ladenburg Thalmann
3 questions for XAIR
Also covers: ARDX, AXSM, CORT +8 more
JK
Jason Kolbert
D Boral Capital
2 questions for XAIR
Also covers: BCDA, CANF, HUMA +7 more
JW
Jason Wittes
Roth Capital Partners, LLC
2 questions for XAIR
Also covers: ALUR, ARAY, ATEC +13 more
MK
Mike King
H.C. Wainwright & Co., LLC
2 questions for XAIR
Also covers: SLRX
IJ
I-Eh Jen
Laidlaw & Company
1 question for XAIR
Also covers: ICAD
Sam Eiber
BTIG, LLC
1 question for XAIR
Also covers: AIRS, APYX, EMBC +8 more
YC
Yale Chen
HC Wainwright & Co.
1 question for XAIR
Recent press releases and 8-K filings for XAIR.
Beyond Air Reports Fiscal Q3 2026 Results, Maintains Guidance, and Announces NeuroNOS Divestiture
XAIR
Earnings
Guidance Update
M&A
- Beyond Air reported fiscal Q3 2026 revenue of $2.2 million, a 105% increase year-over-year, with a net loss of ($7.3) million or ($0.85) per share for the quarter ended December 31, 2025.
- The company maintained its fiscal year 2026 revenue guidance of $8-10 million.
- Pro forma cash, cash equivalents, restricted cash, and marketable securities totaled approximately $22.3 million, including $4.5 million in net proceeds from a recent private placement, providing a cash runway into calendar 2027.
- Beyond Air signed a binding letter of intent for XTL Biopharmaceuticals to acquire 85% of its subsidiary NeuroNOS, with Beyond Air set to receive up to $32.5 million in a combination of upfront cash, development and commercial milestones, and 19.99% equity ownership in XTL Biopharmaceuticals.
- Dan Moorhead was appointed Chief Financial Officer, effective January 5, 2026.
Feb 13, 2026, 9:15 PM
Beyond Air Reports Strong Q3 Fiscal 2026 Results and Announces Neuronas Sale
XAIR
Earnings
M&A
Revenue Acceleration/Inflection
- Beyond Air reported Q3 fiscal 2026 revenue of $2.2 million, a 105% year-over-year increase, with gross profit improving to $300,000 compared to a gross loss in the prior year.
- The company significantly reduced operating expenses by 36% year-over-year to $6.9 million, leading to a net loss of $7.3 million or $0.85 per share, and a 40% reduction in net cash burn to $4.3 million for the quarter ended December 31, 2025.
- Beyond Air announced a binding letter of intent to sell its Neuronas subsidiary for a 19.9% stake in XTL Biopharmaceuticals, $1 million in cash, and up to $31.5 million in milestone payments.
- The company continues to expand the adoption of its LungFit PH system, now supporting over 45 hospitals, and anticipates an FDA decision for its second-generation system before the end of calendar 2026.
Feb 13, 2026, 1:00 PM
Beyond Air Reports Q3 Fiscal 2026 Financial Results and Strategic Updates
XAIR
Earnings
Revenue Acceleration/Inflection
M&A
- Beyond Air reported revenue of $2.2 million for the fiscal quarter ended December 31, 2025 (Q3 fiscal 2026), representing a 105% increase year-over-year and a 21% sequential increase.
- The company achieved a gross profit of $300,000 for Q3 fiscal 2026, a significant improvement from gross losses in the prior year and prior quarter.
- Beyond Air announced the sale of its Neuronas subsidiary in exchange for a 19.9% stake in XTL Biopharmaceuticals, $1 million in cash, and up to $31.5 million in milestone payments.
- The LungFit PH system is now adopted by more than 45 hospitals across the United States and internationally, including a first commercial sale to a VA Medical Center, and its global distribution network has expanded to 40 countries.
- As of December 31, 2025, Beyond Air reported $17.8 million in cash, cash equivalents, restricted cash, and marketable securities, supplemented by a subsequent $4.5 million equity financing. The company anticipates an FDA decision for its second-generation LungFit PH system before the end of calendar 2026.
Feb 13, 2026, 1:00 PM
Beyond Air Reports Q3 Fiscal 2026 Results, Announces Neuronas Sale, and Provides Gen 2 Update
XAIR
Earnings
M&A
Product Launch
- Beyond Air reported Q3 fiscal 2026 revenue of $2.2 million, marking a 105% increase year-over-year, and a net loss of $7.3 million or $0.85 per share, significantly reduced from the prior year.
- The company's net cash burn decreased by over 40% year-over-year to $4.3 million for the quarter, with cash and equivalents at $17.8 million as of December 31, 2025, and an additional $4.5 million equity financing completed in January 2026, providing a cash runway into calendar year 2027.
- Beyond Air announced the sale of its Neuronas subsidiary to XTL Biopharmaceuticals, receiving a 19.9% stake in XTL, $1 million in cash, and up to $31.5 million in milestone payments.
- The company expects an FDA decision for its second-generation LungFit PH system before the end of calendar 2026, which is designed to offer improvements such as extended service intervals and transport compatibility.
- Commercial efforts for LungFit PH continue to expand, now supporting over 45 hospitals and having established new international distribution agreements in 40 countries, including the first sale to a VA Medical Center.
Feb 13, 2026, 1:00 PM
Beyond Air Reports Fiscal Third Quarter 2026 Results and Strategic Updates
XAIR
Earnings
Guidance Update
M&A
- Beyond Air reported $2.2 million in revenue for the fiscal third quarter ended December 31, 2025, marking a 105% increase year-over-year, with a net loss attributed to common stockholders of ($7.3) million or ($0.85) per share.
- The company maintained its fiscal year 2026 revenue guidance of $8-10 million and reported a pro forma cash balance of approximately $22.3 million, which is expected to provide a cash runway into calendar 2027.
- Beyond Air signed a binding agreement for XTL Biopharmaceuticals to acquire 85% of its NeuroNOS subsidiary, with Beyond Air set to receive up to $32.5 million from upfront cash and milestones, along with 19.99% equity ownership in XTL Biopharmaceuticals.
- Dan Moorhead was appointed as Chief Financial Officer, effective January 5, 2026, and Bob Carey will assume the role of Chairman of the Board.
Feb 13, 2026, 12:30 PM
Beyond Air, Inc. Announces $5.0 Million Private Placement
XAIR
Equity Offering
Private Placement
Warrants
- Beyond Air, Inc. entered into a securities purchase agreement with an institutional investor for a private placement, expecting gross proceeds of approximately $5.0 million.
- The company agreed to sell 524,990 shares of common stock at a purchase price of $1.272 per share, pre-funded warrants to purchase up to 3,405,828 shares at $1.2719 per pre-funded warrant, and common warrants to purchase up to 3,930,818 shares.
- The common warrants have an exercise price of $1.147 per share and expire on January 16, 2031, while the pre-funded warrants have an exercise price of $0.0001 per share.
- The offering closed on January 16, 2026, with the net proceeds intended for working capital and general corporate purposes.
- Rodman & Renshaw LLC, acting as the exclusive placement agent, will receive a 7.0% cash fee of the gross proceeds and up to $50,000 in reimbursed expenses.
Jan 20, 2026, 9:30 PM
Beyond Air (XAIR) Discusses Second-Generation Product, International Expansion, and Diverse Pipeline
XAIR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Beyond Air (XAIR) is preparing for the anticipated FDA approval of its second-generation nitric oxide delivery machine before the end of 2026, which is designed to be smaller, more user-friendly, and capable of inter-hospital transport, addressing key limitations of its first-generation product and aiming for majority U.S. market share.
- The company has initiated an aggressive international expansion, securing distribution partners in 40 countries within the last nine months, with the ex-U.S. market expected to be double the U.S. market in dollar value over the next 5-7 years, anticipating significant revenue impact from 2026 into 2027.
- Beyond Air is advancing a diverse nitric oxide-mediated pipeline, including programs for infectious diseases (e.g., NTM lung infection), cancer (with human trial data showing a "big survival signal" to be presented in 2026), and preclinical neurological conditions.
- The company reports having enough cash to reach approval for its next-generation product, with international distribution partners expected to act as a force multiplier for growth and potentially reduce the need for further capital raises.
Jan 15, 2026, 6:30 PM
Beyond Air Details Second-Generation Product and International Growth Strategy
XAIR
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Beyond Air (XAIR) is awaiting FDA approval for its second-generation nitric oxide machine before the end of 2026, which is designed to be smaller, more user-friendly, and includes inter-hospital transport capabilities, with the company anticipating it will help secure a majority of U.S. market share.
- The company has initiated international expansion, establishing distribution partnerships in 40 countries within the last nine months, and projects the ex-U.S. market to be double the U.S. market in dollar value over the next 5-7 years.
- Significant revenue impact from overseas markets is expected to begin in 2026 and become substantial in 2027.
- Beyond Air's pipeline includes applications of nitric oxide for infectious diseases, cancer (showing promising survival data in refractory patients), and neurological conditions such as Phelan-McDermid syndrome and glioblastoma.
- The company has sufficient cash to reach approval for its next-generation product and holds patents for its LungFit machine extending to 2040, with potential for the second-generation to reach 2044.
Jan 15, 2026, 6:30 PM
Beyond Air Highlights Product Advantages, Pipeline, and International Growth Strategy
XAIR
Product Launch
New Projects/Investments
Guidance Update
- Beyond Air's nitric oxide system offers significant advantages over cylinder-based and chemical-based competitors, including safety, ease of use, and cost-effectiveness, and has secured 40 international distribution partners since spring 2025.
- The company anticipates FDA approval for its second-generation device before the end of 2026, which is smaller, more user-friendly, and includes critical transport capabilities, addressing limitations of the first-generation product.
- Beyond Air projects the ex-U.S. market to be double the dollar value of the U.S. market over the next 5-7 years, with significant revenue impact from international sales expected in 2027.
- The company is advancing a diverse nitric oxide-mediated pipeline, including infectious disease programs, promising early human data in cancer (25,000-50,000 parts per million NO), and preclinical neurological programs, with patents extending past 2040.
- Beyond Air has sufficient cash to reach approval of its next-generation product and may seek additional capital for a proper launch, while leveraging international distributors to multiply growth.
Jan 15, 2026, 6:30 PM
Beyond Air Announces Sale of Majority Stake in NeuroNOS to XTL Biopharmaceuticals
XAIR
M&A
New Projects/Investments
- XTL Biopharmaceuticals Ltd. (XTLB) entered a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (XAIR), on January 13, 2026.
- As part of the transaction, Beyond Air will hold 19.99% of XTL's post-transaction share capital.
- Beyond Air is also set to receive $1 million in cash and up to $31.5 million in milestone-based contingent payments, totaling up to $32.5 million.
- NeuroNOS, which focuses on disease-modifying therapeutics for Autism Spectrum Disorder, has secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.
Jan 14, 2026, 11:47 PM
Quarterly earnings call transcripts for Beyond Air.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more